An Open-Label, Single-dose, Randomized, Crossover Study to Determine the Bioavailability and Bioequivalence of Alogliptin 12.5 mg and Metformin 1000 mg When Administered as Individual Tablets and as a Fixed-Dose Combination Tablet Vipdomet (Alogliptin FDC With Metformin) in Russian Healthy Subjects

Name: An Open-Label, Single-dose, Randomized, Crossover Study to Determine the Bioavailability and Bioequivalence of Alogliptin 12.5 mg and Metformin 1000 mg When Administered as Individual Tablets and as a Fixed-Dose Combination Tablet Vipdomet (Alogliptin FDC With Metformin) in Russian Healthy Subjects
Creator: Vivli
Published: 2025-05-01 01:02:41
License: 暂无描述

DataCite Commons2025-05-01 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/00003263/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

The purpose of this study is to determine the relative bioavailability of alogliptin 12.5 milligram (mg) and immediate-release metformin 1000 mg when administered as individual tablets and as a fixed-dose combination (FDC) product.

提供机构：

Vivli

创建时间：

2018-11-01